Roche, Blueprint Medicines sign $1.7bn worth deal for pralsetinib

Roche, Blueprint Medicines sign $1.7bn worth deal for pralsetinib

Source: 
Pharmaceutical Business Review
snippet: 


Roche and Blueprint Medicines have signed a global licensing and collaboration deal worth up to $1.7bn for the latter's pralsetinib, an investigational treatment for RET-altered cancers.